Association of circulating vitamin D concentrations with intestinal but not systemic inflammation in inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 19, Issue 12, 2013, Pages 2634-2643

  Garg, Mayur ^a,b   Rosella, Ourania ^b   Lubel, John S ^a,b   Gibson, Peter R ^b  

^a Eastern Health ^*  (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Bioavailable vitamin D; Crohn's disease; Free vitamin D; Inflammatory bowel disease; Ulcerative colitis; Vitamin D; Vitamin D binding protein

Indexed keywords

25 HYDROXYVITAMIN D; C REACTIVE PROTEIN; CALGRANULIN; VITAMIN BINDING PROTEIN;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; HUMAN; LIGHT EXPOSURE; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; SUNLIGHT; THROMBOCYTE COUNT; ULCERATIVE COLITIS; VITAMIN BLOOD LEVEL; VITAMIN INTAKE; WAIST CIRCUMFERENCE;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; INTESTINAL MUCOSA; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; VITAMIN D; YOUNG ADULT;

EID: 84888345228     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.MIB.0000436957.77533.b2     Document Type: Article

References (64)

1. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362: 1383-1395.
2. Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785-1794.
3. Access economics. The economic costs of Crohn's disease and ulcerative colitis. Available at: https://www.crohnsandcolitis.com.au/content/Deloitte- Access-Economics-Report.pdf. Accessed June 15, 2012.
4. Garg M, Lubel JS, Sparrow MP, et al. Review article: vitamin D and inflammatory bowel disease - established concepts and future directions. Aliment Pharmacol Ther. 2012;36:324-344.
5. van Hogezand RA, Hamdy NA. Skeletal morbidity in inflammatory bowel disease. Scand J Gastroenterol Suppl. 2006:59-64.
6. Ross AC, ed. Institute of Medicine of the National Academies 2011 Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: The National Academies Press; 2011.
7. Pilz S, Tomaschitz A, Marz W, et al. Vitamin D, cardiovascular disease and mortality. Clin Endocrinol (Oxf). 2011;75:575-584.
8. Manson JE, Mayne ST, Clinton SK. Vitamin D and prevention of cancer - ready for prime time? N Engl J Med. 2011;364:1385-1387.
9. Niino M. Vitamin D and its immunoregulatory role in multiple sclerosis. Drugs Today (Barc). 2010;46:279-290.
10. Martineau AR, Timms PM, Bothamley GH, et al. High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet. 2011;377:242-250.
11. Wilson J, Hair C, Knight R, et al. High incidence of inflammatory bowel disease in Australia: a prospective population-based Australian incidence study. Inflamm Bowel Dis. 2010;16:1550-1556.
12. Khalili H, Huang ES, Ananthakrishnan AN, et al. Geographical variation and incidence of inflammatory bowel disease among US women. Gut. 2012;61:1686-1692.
13. Ananthakrishnan AN, Khalili H, Higuchi LM, et al. Higher predicted Vitamin D status is associated with reduced risk of Crohn's disease. Gastroenterology. 2012;142:482-489.
14. Baumgart DC, Bernstein CN, Abbas Z, et al. IBD around the world: comparing the epidemiology, diagnosis, and treatment: proceedings of the World Digestive Health Day 2010-Inflammatory bowel disease task force meeting. Inflamm Bowel Dis. 2011;17:639-644.
15. Gearry RB, Richardson A, Frampton CM, et al. High incidence of Crohn's disease in Canterbury, New Zealand: results of an epidemiologic study. Inflamm Bowel Dis. 2006;12:936-943.
16. Carr I, Mayberry JF. The effects of migration on ulcerative colitis: a threeyear prospective study among Europeans and first- and second-generation South Asians in Leicester (1991-1994). Am J Gastroenterol. 1999;94: 2918-2922.
17. Moum B, Aadland E, Ekbom A, et al. Seasonal variations in the onset of ulcerative colitis. Gut. 1996;38:376-378.
18. Zeng L, Anderson FH. Seasonal change in the exacerbations of Crohn's disease. Scand J Gastroenterol. 1996;31:79-82.
19. Nerich V, Jantchou P, Boutron-Ruault MC, et al. Low exposure to sunlight is a risk factor for Crohn's disease. Aliment Pharmacol Ther. 2011; 33:940-945.
20. Jorgensen SP, Hvas CL, Agnholt J, et al. Active Crohn's disease is associated with low vitamin D levels. J Crohns Colitis. 2013;7:e407-e413.
21. Ananthakrishnan AN, Cagan A, Gainer VS, et al. Normalization of plasma 25-hydroxy Vitamin D is associated with reduced risk of surgery in Crohn's disease. Inflamm Bowel Dis. 2013;19:1921-1927.
22. Hassan V, Hassan S, Seyed-Javad P, et al. Association between serum 25 (OH) Vitamin D concentrations and inflammatory bowel diseases (IBDs) activity. Med J Malaysia. 2013;68:34-38.
23. Jorgensen SP, Agnholt J, Glerup H, et al. Clinical trial: vitamin D3 treatment in Crohn's disease - a randomized double-blind placebo-controlled study. Aliment Pharmacol Ther. 2010;32:377-383.
24. Miheller P, Muzes G, Hritz I, et al. Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn's disease patients. Inflamm Bowel Dis. 2009;15:1656-1662.
25. Boothe DL, Lakehomer H, Jacob V, et al. High Dose Vitamin D Improves Clinical Activity in Crohn's Disease. Washington, DC: American College of Gastroenterology; 2011.
26. Mawer EB, Backhouse J, Holman CA, et al. The distribution and storage of vitamin D and its metabolites in human tissues. Clin Sci. 1972;43:413-431.
27. Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr. 2008; 88:582S-586S.
28. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911-1930.
29. Powe CE, Ricciardi C, Berg AH, et al. Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. J Bone Miner Res. 2011;26:1609-1616.
30. Otterbein LR, Cosio C, Graceffa P, et al. Crystal structures of the vitamin D-binding protein and its complex with actin: structural basis of the actinscavenger system. Proc Natl Acad Sci U S A. 2002;99:8003-8008.
31. Mendel CM. The free hormone hypothesis: a physiologically based mathematical model. Endocr Rev. 1989;10:232-274.
32. Bhan I, Powe CE, Berg AH, et al. Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients. Kidney Int. 2012;82:84-89.
33. Nykjaer A, Dragun D, Walther D, et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell. 1999;96:507-515.
34. Rowling MJ, Kemmis CM, Taffany DA, et al. Megalin-mediated endocytosis of vitamin D binding protein correlates with 25-hydroxycholecalciferol actions in human mammary cells. J Nutr. 2006;136:2754-2759.
35. Atkins GJ, Anderson PH, Findlay DM, et al. Metabolism of vitamin D3 in human osteoblasts: evidence for autocrine and paracrine activities of 1 alpha, 25-dihydroxyvitamin D3. Bone. 2007;40:1517-1528.
36. van Driel M, Koedam M, Buurman CJ, et al. Evidence for auto/paracrine actions of vitamin D in bone: 1alpha-hydroxylase expression and activity in human bone cells. FASEB J. 2006;20:2417-2419.
37. Chun RF, Lauridsen AL, Suon L, et al. Vitamin D-binding protein directs monocyte responses to 25-hydroxy- and 1,25-dihydroxyvitamin D. J Clin Endocrinol Metab. 2010;95:3368-3376.
38. Low Vitamin D in Victoria: Key messages for Doctors, Nurses and Allied Health. Melbourne, Australia: Victorian Government Department of Health, 2012.
39. Food Standards Australia New Zealand NUTTAB 2010. Government of Australia Department of Health and Ageing, 2010.
40. Fitzpatrick TB. Soleil et peau. J Med Esthet. 1975;2:33-34.
41. Bikle DD, Gee E, Halloran B, et al. Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein. J Clin Endocrinol Metab. 1986;63:954-959.
42. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84:3666-3672.
43. Yu S, Bruce D, Froicu M, et al. Failure of T cell homing, reduced CD4/ CD8alphaalpha intraepithelial lymphocytes, and inflammation in the gut of vitamin D receptor KO mice. Proc Natl Acad Sci U S A. 2008; 105:20834-20839.
44. Cantorna MT, Munsick C, Bemiss C, et al. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr. 2000;130:2648-2652.
45. Daniel C, Sartory NA, Zahn N, et al. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J Pharmacol Exp Ther. 2008;324:23-33.
46. Laverny G, Penna G, Vetrano S, et al. Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease. Immunol Lett. 2010;13149-58.
47. Ulitsky A, Ananthakrishnan AN, Naik A, et al. Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life. JPEN J Parenter Enteral Nutr. 2011;35:308-316.
48. Silvennoinen J. Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel disease. J Intern Med. 1996;239:131-137.
49. Tajika M, Matsuura A, Nakamura T, et al. Risk factors for vitamin D deficiency in patients with Crohn's disease. J Gastroenterol. 2004;39: 527-533.
50. McCarthy D, Duggan P, O'Brien M, et al. Seasonality of vitamin D status and bone turnover in patients with Crohn's disease. Aliment Pharmacol Ther. 2005;21:1073-1083.
51. Siffledeen JS, Siminoski K, Steinhart H, et al. The frequency of vitamin D deficiency in adults with Crohn's disease. Can J Gastroenterol. 2003;17: 473-478.
52. Levin AD, Wadhera V, Leach ST, et al. Vitamin D deficiency in children with inflammatory bowel disease. Dig Dis Sci. 2011;56:830-836.
53. Michos ED, Streeten EA, Ryan KA, et al. Serum 25-hydroxyvitamin d levels are not associated with subclinical vascular disease or C-reactive protein in the old order amish. Calcif Tissue Int. 2009;84:195-202.
54. Ewers B, Gasbjerg A, Zerahn B, et al. Impact of vitamin D status and obesity on C-reactive protein in kidney-transplant patients. J Ren Nutr. 2008;18:294-300.
55. Amer M, Qayyum R. Relation between serum 25-hydroxyvitamin D and C-reactive protein in asymptomatic adults (from the continuous National Health and Nutrition Examination Survey 2001 to 2006). Am J Cardiol. 2012;109:226-230.
56. Baykal T, Senel K, Alp F, et al. Is there an association between serum 25-hydroxyvitamin D concentrations and disease activity in rheumatoid arthritis? Bratisl Lek Listy. 2012;113:610-611.
57. Sipponen T, Savilahti E, Kolho KL, et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008;14:40-46.
58. Vieth R, ed. The Pharmacology of Vitamin D, Including Fortification Strategies. 2nd ed. London, United Kingdom: Elsevier; 2005.
59. Chapuy MC, Preziosi P, Maamer M, et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int. 1997;7: 439-443.
60. Kuchuk NO, van Schoor NM, Pluijm SM, et al. Vitamin D status, parathyroid function, bone turnover, and BMD in postmenopausal women with osteoporosis: global perspective. J Bone Miner Res. 2009;24:693-701.
61. Molander P, af Bjorkesten CG, Mustonen H, et al. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFalpha blocking agents. Inflamm Bowel Dis. 2012;18:2011-2017.
62. Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol. 2004;39:1017-1020.
63. Simmons JD, Mullighan C, Welsh KI, et al. Vitamin D receptor gene polymorphism: association with Crohn's disease susceptibility. Gut. 2000;47:211-214.
64. Emmen JM, Wielders JP, Boer AK, et al. The new Roche Vitamin D total assay: fit for its purpose? Clin Chem Lab Med CCLM/FESCC. 2012;0:1-4.